Single dose Rasburicase is a clinically effective pharmacoeconomic approach for preventing tumour lysis syndrome in children with high tumour burden.

Syrimi, Eleni; Gunasekera, Sanjeeva; Norton, Alice; Velangi, Mark; Motwani, Jayashree; Hiwarkar, Prashant

Syrimi, Eleni; Gunasekera, Sanjeeva; Norton, Alice; Velangi, Mark; Motwani, Jayashree; Hiwarkar, Prashant.

Afiliación

Syrimi E; Department of Haematology, Birmingham Children's Hospital, Birmingham, UK.
Gunasekera S; Department of Haematology, Birmingham Children's Hospital, Birmingham, UK.
Norton A; Department of Haematology, Birmingham Children's Hospital, Birmingham, UK.
Velangi M; Department of Haematology, Birmingham Children's Hospital, Birmingham, UK.
Motwani J; Department of Haematology, Birmingham Children's Hospital, Birmingham, UK.
Hiwarkar P; Department of Haematology, Birmingham Children's Hospital, Birmingham, UK.

Br J Haematol ; 181(5): 696-698, 2018 06.

Article en En | MEDLINE | ID: mdl-28480955

Asunto(s)

Neoplasias/terapia; Síndrome de Lisis Tumoral/prevención & control; Urato Oxidasa/administración & dosificación; Adolescente; Niño; Preescolar; Femenino; Humanos; Lactante; Masculino; Neoplasias/sangre; Estudios Retrospectivos; Síndrome de Lisis Tumoral/sangre

Palabras clave

hyperuricaemia; single dose rasburicase; tumour lysis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Urato Oxidasa / Síndrome de Lisis Tumoral / Neoplasias Tipo de estudio: Observational_studies Límite: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Br J Haematol Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google